… A GWAS of cisplatin-induced peripheral neuropathy … three neurotoxicities (hearing loss,
tinnitus, and peripheral neuropathy). … with cisplatin-induced hearing loss, tinnitus, and peripheral …

… for Chemotherapy-Induced Long-Term Neurotoxicity score, which also includes self-reported
hearing loss and tinnitus… no other pharmacogenomic studies of CIPN in which cisplatin was …

… chemotherapy for many cancers, but causes neurotoxicity, including hearing loss (CisHL),
tinnitus (CisTinn), and peripheral … comorbidities for cisplatin-induced neurotoxicities among …

… with cisplatin-induced ototoxicity and neurotoxicity because … in pharmacogenomic studies
related to cisplatin is likely due … contrast to hearing loss (a quantitative phenotype), peripheral …

… Therefore, the incorporation of gene-based analyses in pharmacogenomic studies can be
… patients with severe hearing loss, tinnitus, and/or peripheral sensory neuropathy following …

… subjective hearing loss, ear pain and tinnitus Citation[11]. … Genotyping was carried out with
peripheral blood … , nephrotoxicity, neurotoxicity, ototoxicity and intellectual impairment. This …

… some degree of tinnitus during cisplatin-based ChT, and … to a lower incidence of
cisplatin-induced hearing loss without … thiosulfate against cisplatin-induced hearing loss in …

… These include hearing impairment, tinnitus, renal dysfunction, cardiovascular disease, …
to assess its role in the pathophysiology of neurotoxicity, possibly revealing novel targets. …

… for Chemotherapy-Induced Long-Term Neurotoxicity score, which also includes self-reported
hearing loss and tinnitus… reported pharmacogenomic studies of CIPN in which cisplatin was …

… hearing loss (HL) or tinnitus were more likely to fill out the questionnaire (eg, response bias),
we determined how many of the 371 patients had reported HL/tinnitus … -Term Neurotoxicity …